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Abstract
Preeclampsia is a common complication of pregnancy characterized by hypertension and proteinuria. Its symptoms are well-defined, but the pathophysiology is not fully understood. This paper analyzes several of the most credible causes of this syndrome
and attempts to relate these to the known risk factors. Current preeclampsia treatments are examined, and special focus is given
to novel experimental treatments which offer hope of ending preeclampsia and eclampsia.
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Introduction
Preeclampsia is a relatively common complication of pregnancy.
Occurring in 7% of all pregnancies in the US, it is defined as an increase in blood pressure combined with proteinuria. More severe
cases of preeclampsia have the potential to advance into eclampsia,
which is preeclampsia with the addition of seizures. Preeclampsia
and eclampsia have the ability to cause lasting harm or death to
both mother and fetus, but the cause of these diseases is largely
unclear (Papadakis & McPhee, 2017).
Risk factors for preeclampsia are known. Hypertension, kidney
disease, family history, diabetes, and obesity are all linked to a higher incidence of preeclampsia. Preeclampsia is commonly called a
disease of the first pregnancy, though women who have had preeclampsia before are also at greater risk of developing it in subsequent pregnancy. Strangely enough, cigarette smoking seems to
prevent preeclampsia.There are other known risk factors as well.
Some of the pathophysiology of preeclampsia is understood.
It is believed that preeclampsia develops from poor placentation and the release of soluble fms-like tyrosine kinase 1 (sFlt1)
into the mother’s bloodstream. However, the increase in sFlt1
levels is often not distinct enough to use as a screening tool.
Additionally, the original cause of the increase is unknown.
Treatment of preeclampsia is largely based on symptoms, with
the goal being the continuation of the pregnancy for as long
as possible. Almost all symptoms disappear within 48 hours
after delivery, so it is in the mother’s best interest to give birth.
Conversely, the fetus needs more time in utero to develop. The

physician must balance the conflicting needs of the two patients
by managing the mother’s symptoms. Further understanding of
the underlying causes of preeclampsia can result in more effective treatment and better outcomes for preeclamptic women
and their children.

Methods
Peer-reviewed journal articles were obtained using Touro
College’s database and Google Scholar. The articles were critically read, analyzed, and compared. Special attention was given
to retrospective studies and reviews due to the dearth of original studies in their references. This can be attributed to the fact
that pregnant women tend to be apprehensive about joining
clinical studies.

Discussion
Symptoms of Preeclampsia
Preeclampsia is a complication of pregnancy involving hypertension and proteinuria. It cannot be prevented. Instead, pregnant
women are screened for symptoms and treated accordingly.
These symptoms usually present in the third trimester, but can
occur from 20 weeks’ gestation. It is diagnosed when a patient
presents with blood pressure of 140/90 or greater, and more
than 0.3 g of proteinuria in 24 hours. Some women also have
edema. Severe preeclampsia involves higher blood pressure
as well as thrombocytopenia, headache, and blurred vision
(Papadakis & McPhee, 2017).
Severe preeclampsia is also characterized by hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome.
This diagnosis was first made in 1982 and is currently found
in 0.2-0.8% of pregnancies. HELLP syndrome is rarely seen in
non-preeclamptic patients, though preeclampsia is about ten
times as common as HELLP. Like preeclampsia, HELLP is a syndrome, a collection of symptoms whose one underlying cause is
uncertain.The hemolysis aspect is a result of damaged endothelial cells in small blood vessels. Fibrin strands in the blood vessels cause red blood cells to become fragmented, often causing
anemia. Microangiopathy also slows hepatic portal blood flow,
damaging the liver. The same microangiopathy also exposes
tissue factor on blood vessel walls which activates coagulation
pathways. These blood clots lower platelet counts and can lead
to further complications such as uncontrolled bleeding or placental abruption (Abildgaard & Heimdal, 2013).
If preeclampsia continues, it can develop into eclampsia, which
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is defined as all of the symptoms of preeclampsia with the addition of seizures. Eclampsia is easily prevented by administration
of magnesium, so it is usually only seen in patients lacking prenatal care, or in developing countries where access to this anticonvulsant is unavailable. Hyperexcitability and extreme reflex
responses are typical signs that eclampsia may be developing
(Papadakis & McPhee, 2017; Duley, 2009).
Preeclampsia is primarily a disease of the mother, so the fetus is
not always affected. This is especially true in milder cases of preeclampsia, where the pregnancy is allowed to continue until term.
However, this is not to say that the fetus is never endangered.
Fetal growth restriction is a complication often correlated with
preeclampsia. Because of the mother’s angiopathy, blood supply to
the fetus can be reduced.This does not allow the fetus to receive
adequate nutrition, causing a low birth weight (Duley, 2009).
More seriously, preeclampsia often forces an early delivery because of the mother’s symptoms. Preterm delivery, in this case
meaning before 34 weeks’ gestation, is associated with various
complications. There is the immediate problem of insufficient
surfactant maturity in the lungs, causing the baby to go into respiratory distress upon birth. Low birth weight often causes complications later in life, including cardiovascular problems, diabetes,
and obesity. Additionally, increased risk of cerebral palsy has been
associated with children of preeclamptic mothers. Although preeclampsia primarily affects the mother, the fetus is not spared of
all effects (Papadakis & McPhee, 2017; Duley, 2009).

Causes of Preeclampsia
The causes of preeclampsia are poorly understood. Because
preeclampsia is a syndrome, a collection of symptoms which
may or may not come from one underlying cause, the pathogenesis can be different for different patients. Most people agree
that preeclampsia’s cause lies in the placenta due to the fact
that the disease disappears upon delivery. It is hypothesized
that poor placentation is a cause of preeclampsia. In normal
pregnancies, cytotrophoblasts from the placenta invade the
mother’s myometrium and increase blood supply to the fetus. In
preeclamptic placentas, insufficient invasion and remodeling of
the mother’s arteries occur. The placenta is therefore hypoxic,
and parts of it break down and release debris into maternal
circulation. This debris, containing trophoblast cells and keratin
fragments, causes the inflammatory response of preeclampsia,
microangiopathy and hypertension (Redman & Sargent, 2005).
Normal placentas release vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF). Both are angiogenic
factors which allow the placenta to build an adequate vascular
network for the fetus’s development.When VEGF or PlGF binds
to a receptor on placental cell surfaces, increased vascularity is
shown. A soluble form of this receptor, soluble fms-like tyrosine
kinase-1 (sFlt1), increases in the third trimester. This receptor
floats freely in the placenta and maternal serum. When sFlt1
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binds to VEGF or PlGF, they are unable to create blood vessels,
proving sFlt1 to be antiangiogenic, and possibly the cause of
the poor placentation described above. This factor is further
increased in preeclampsia, and is found to increase even before
clinical signs of the syndrome are evident. It is believed that
excess sFlt1 can cause preeclampsia; what is unknown is how
this excess develops in the first place and what can be done to
prevent it (Redman & Sargent, 2005; Levine et al., 2004).
It is believed that decreased free VEGF and PlGF in the maternal blood supply leads to the endothelial dysfunction of preeclampsia. In the kidneys, the lack of free VEGF causes glomerular endotheliosis; constantly circulating VEGF is necessary for
renal function. The swelling of kidney cells then does not allow
for proper filtration of the blood, causing proteinuria. Exactly
how or if sFlt1 causes hypertension is unknown.
As would be expected, women with lower VEGF and PlGF levels and higher sFlt1 levels tend to have more severe symptoms
of preeclampsia and eclampsia.Additionally, when sFlt1 is administered to nonpregnant rats, they develop preeclamptic symptoms.
VEGF inhibitors or VEGF gene knockouts cause hypertension and
proteinuria in pregnant and nonpregnant rats. Cancer patients
taking VEGF-inhibitors to limit blood supply to a tumor will also
often exhibit hypertension and proteinuria, further proving the
role of sFlt1 in preeclampsia (Levine et al., 2004).
Preeclampsia is widely considered a disease of the nulliparous woman. In a Norwegian study examining data from over
700,000 births between 1967 and 1998, preeclampsia was found
in 3.9% of first pregnancies (Skjærven et al., 2002). This is compared to a 1.7% incidence for second pregnancies, and 1.8% for
third. The incongruous increase for third pregnancies is quite
small and probably a statistical artifact. It is unknown exactly
why preeclampsia is much more common in first pregnancies.
What is known is that if a mother was preeclamptic in her first
pregnancy, she is at risk for preeclampsia in later pregnancies
as well. Somehow, nulliparity seems to cause preeclampsia. This
Norwegian study claims that preeclampsia is a result of the
mother being exposed to her partner’s foreign antigens and
responding inflammatorily, causing preeclampsia. In later pregnancies by the same man, preeclampsia is less likely because
the partner’s antigens are no longer unrecognized by her body.
Giving weight to this theory, the more time that elapsed between pregnancies, the more likely the mother was to develop
preeclampsia, even if she had not previously been preeclamptic. As time passed, the immune system’s ability to recognize a
partner’s antigens decreased. Women whose second pregnancies were by different partners appear to have the same risk of
preeclampsia as nulliparous women. This supports the idea that
preeclampsia is partially caused by foreign antigens; a new partner supplies new antigens for which the mother is unprepared.
However, since women who have changed partners often have a
larger birth interval, it is very uncertain if the change in partner
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actually increases the risk for preeclampsia. Interestingly, previous miscarriage seems to reduce the risk of preeclampsia in
a later, successful pregnancy. This can also be connected to the
idea of interbirth interval, as many women who miscarry attempt to get pregnant again very soon thereafter. Nulliparity is
known to be a risk factor for preeclampsia; the reason for this is
not totally clear (Skjærven et al., 2002; Sibai et al., 1995).

Risk Factors
There are many risk factors for preeclampsia, including chronic
hypertension and kidney dysfunction, obesity, diabetes, previous
preeclamptic pregnancies, family history of the mother or father,
birth interval, age of the mother, as well as other preexisting
conditions. This paper will analyze some of the more credible
risk factors and attempt to explain the connection between
them and the disease.
Nulliparity is the most known risk factor for preeclampsia.
Whether this is due to an immune response or some other
mechanism is largely unknown. What is known is that nulliparous women are more than three times more likely to develop
preeclampsia than women who have previously had normotensive pregnancies (Duckitt & Harrington, 2005).
Women with chronic hypertension unrelated to their
pregnancy are known to have a higher risk of developing preeclampsia and eclampsia. In one population-based study, 12.1%
of preeclamptic women were found to have had hypertension
before they became pregnant (Duckitt & Harrington, 2005).This
is quite logical; high blood pressure before becoming pregnant
leads to even higher blood pressure while pregnant. Clinically,
blood pressure is used to diagnose preeclampsia. Preeclampsia
is defined as systolic blood pressure of 140 mmHg or greater
and/or diastolic blood pressure of 90 mmHg or greater, and at
least 300 mg of proteinuria over 24 hours. Blood pressure can
also be used to screen for preeclampsia. Elevated blood pressure is normal in pregnancy, but too high an elevation can be a
sign that preeclampsia will develop. In one study of nearly 3000
women, the mean systolic blood pressure at 20 weeks gestation
was 105.4 for healthy pregnancies, and 110.4 for those who
later developed preeclampsia.This is a substantial difference, but
clinically it would be difficult to gain any benefit from this statistic. Diastolic and mean blood pressure were not as useful for
prediction. Not surprisingly, women who displayed significantly
elevated blood pressure at 20 weeks were more likely to develop preeclampsia earlier than those whose blood pressure was
not as elevated. This is a more useful diagnostic tool. Systolic
blood pressure of 110 as opposed to 105 is hardly grounds to
begin watching more closely for preeclampsia. Systolic blood
pressure of 125 or 130 is (Sibai et al., 1995).
As with hypertension, kidney dysfunction before pregnancy
is likely to lead to increased kidney dysfunction while pregnant, i.e. preeclampsia. Less research has been done on kidney

dysfunction leading to preeclampsia, though. In one study of 69
pregnancies, 6.7% of women with recurring urinary tract infections developed preeclampsia, and only 2.6% of the control
group did. In other words, 2 of the 39 women with renal disease developed preeclampsia, and only 1 healthy woman did.
This is hardly enough evidence on which to build a treatment
plan. Logically, the connection between renal disease and preeclampsia seems just as strong as that between hypertension
and preeclampsia. However, not nearly as much research was
done on this juxtaposition, perhaps because of the relative rarity of renal disease in women of childbearing age (Duckitt &
Harrington, 2005).
Non-gestational diabetes greatly increases the risk of preeclampsia. A meta-analysis of multiple studies with a total
count of 56,968 women revealed that the risk of developing
preeclampsia is 3.56% greater for women who have diabetes
before pregnancy. These studies are often connected to studies
linking preeclampsia and obesity, which also approximately quadruples the risk of preeclampsia. Because women with diabetes
and high BMI often have other health problems, it is difficult
to assess exactly which of their characteristics make them
more likely to develop preeclampsia (Sibai et al., 1995; Duckitt
& Harrington, 2005). In a Saudi Arabian study of the effects of
obesity and gestational diabetes on pregnancy, it was found that
approximately 7% of women with obesity and/or gestational diabetes develop preeclampsia, compared to only 0.5% of women
with neither. The combination of the two seems to increase the
risk (Wahabi et al., 2014).
The connection between obesity and preeclampsia has been
linked to inflammation. Obesity is inflammatory, as is preeclampsia, so it stands to reason that one inflammatory state can cause
the development of an inflammatory disease. Additionally, preeclampsia often develops from hypoxic conditions in the placenta. Obesity can encourage this. Obesity is often linked with
hyperglycemia, causing hemoglobin to pick up glucose and lose
its affinity for oxygen. This does not allow enough oxygen to
reach the placenta, leading to an inflammatory response, the
release of cytokines, and subsequent endothelial dysfunction of
preeclampsia (Redman & Sargent, 2005; Schmatz et al., 2010).
Previously having preeclampsia puts a woman up to seven
times at risk for developing the disease in subsequent pregnancies when compared to women who have never had preeclampsia. It is assumed that whatever caused her to be susceptible in
the first place will also cause later incidences of preeclampsia.
A family history also puts a woman more at risk, though the
mother-in-law’s pregnancies do not seem to have much of an
effect (Sibai et al., 1995; Duckitt & Harrington, 2005).

Treatment
Treatment options for preeclampsia are largely based on symptoms. The best treatment is delivery, but immediate delivery is
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not always an option. Other treatments therefore are based on
prolonging the pregnancy for as long as possible, keeping the
mother’s health in mind (Papadakis & McPhee, 2017).
When systolic blood pressure rises above 160 mmHg, or diastolic above 110, antihypertensive drugs are administered to
bring blood pressure back down to 140/90, the threshold for
preeclampsia’s diagnosis. In severe preeclampsia, steps are taken
to ensure that the patient will not develop eclampsia. If the
mother begins to experience muscle spasms or hyperexcitability, showing that her CNS is beginning to be affected, magnesium
sulfate is administered as a relaxant. Magnesium is also given to
patients with eclampsia. Obviously, these women are monitored
for toxicity. Calcium has been suggested as an aid in preeclampsia, but no real benefits have been proven (Papadakis & McPhee,
2017; Levine et al., 2004).
Delivery is the best option for the mother, and it is the treatment of choice from 36 weeks onward. Before that point, clinicians must decide if the fetus is ready for life outside the womb.
If the fetus’s lungs are not mature enough for birth, corticosteroids are administered to the mother for 48 hours, followed
by induced delivery or cesarean. The steroids allow the fetus’s
lungs to mature more quickly. If the mother’s symptoms are
severe, such as in eclampsia, waiting for fetal lung maturation is
not necessarily an option. Delivery must then be induced to the
detriment of the fetus (Papadakis & McPhee, 2017).
Preeclampsia is a major cause of preterm delivery. Early delivery is often necessary for the mother’s sake; the child suffers.
Premature birth can result in respiratory distress, admittance to
the NICU, low birth weight, jaundice, seizures, as well as other
complications in infancy and later in life (Papadakis & McPhee,
2017). Fetal mortality is a large concern; preeclampsia is correlated with 25% of stillbirths and neonatal deaths in developing
countries (Duley, 2009).
Both aspirin and nicotine appear to reduce the risk of preeclampsia. Aspirin has antihypertensive properties, so its role in
decreasing the incidence of preeclampsia makes sense. In one
study of healthy, nulliparous women, 4.6% of those given aspirin
developed preeclampsia, compared to 6.9% of those given placebo. However, the aspirin did increase the risk of abruptio placentae, which makes the idea of treating all pregnant women with
aspirin less appealing (Sibai et al., 1993). It is recommended by
some for women at high risk for preeclampsia (Sibai et al., 1995).
Cigarette smoking is known to decrease the risk of preeclampsia, but doctors are hardly likely to begin advising smoking during pregnancy. One explanation for this phenomenon is
that nicotine appears to play a role in reducing the amount of
sFlt1 in the mother’s bloodstream. This ameliorates preeclampsia’s antiangiogenic effects and does not allow inflammation to
cause the mother to develop hypertension and proteinuria.
Even if smokers develop preeclampsia, it is usually not very severe. In a clinical trial testing aspirin’s effect, 5.9% of nonsmokers
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developed preeclampsia, compared to 2.7% of those who quit
during pregnancy, and 3.7% of those who smoked throughout.
The many negative effects of cigarette smoking on both mother
and child, though, far outweigh the small shielding from preeclampsia’s effects (Sibai et al., 1993; Jeyabalan et al., 2008).
The current treatments for preeclampsia are less than ideal,
but experimental treatments may give us some better options.
It is important to note that designing preclinical and clinical trials for these treatments can be quite difficult. Animal models are
often less than ideal as these animals may have very different
placentas than humans. Many of these trials involve animals that
do not ever develop preeclampsia. Scientists instead create situations to mimic preeclampsia’s symptoms in vivo. Moving on to
a clinical trial in humans will only occur after extensive testing.
Nobody wants a repeat of the thalidomide disaster, so advancement in pregnancy treatment moves slowly (Sibley, 2017).
In a 2016 study of 28 rats, apelin was used to successfully
ameliorate symptoms of preeclampsia. Apelin is a peptide found
in the cardiovascular system. Among other effects, it reduces
blood pressure in atherosclerosis and encourages angiogenesis. In this experiment, half of the rats served as control (N
group), and half of these were given apelin (N+APLN group),
an angiogenic factor naturally present in mammalian placentas.
Preeclamptic placentas usually have lower apelin than normal.
The acceptable rat model of preeclampsia was used on half the
rats (PE and PE+APLN); uterine arteries were clamped to prevent adequate blood flow to the placenta, leading to the release
of cytokines and debris causing hypertension and proteinuria.
Half of these rats were then treated with apelin. The rats given
apelin had lower blood pressure and proteinuria than the preeclamptic control, but not as low as the healthy rats. Apelin also
increased fetal survival rate and birth weight. One hundred percent of N and N+APLN embryos survived, 25% of PE survived,
and 50% of PE+APLN survived. Considering that fetal survival
rate for humans with preeclampsia is much better than 25%,
it is reasonable to believe that apelin would cause even better
survival rates in humans. The effect on preeclampsia’s maternal
symptoms are also likely to carry over. However, as apelin was
only tested on 8 preeclamptic rats, and because rat placentas
differ greatly from human ones, much more research must be
done before apelin is the drug of choice for preeclampsia (Sibley,
2017; Wang et al., 2017).
Researchers have also recommended mediating the effect of
sFlt1 on the mother’s body by somehow increasing the levels of
VEGF in the placenta. One method of doing so is by injecting
adenovirus vectors for VEGF into the placenta. This was done
in sheep and guinea pig models, as well as in human placentas
in vitro. The increase in VEGF levels mediates the inactivation
of VEGF by sFlt1, resulting in an approximately normal quantity of angiogenic factors. This appears to create normal uterine
blood flow and cure preeclampsia. The virus vector also does
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not appear to cross the placenta and cause other complications.
This treatment is extremely promising and is moving towards
clinical trial in Europe (Sibley, 2017).

Conclusion
Preeclampsia is a major obstetrical complication still common
in the developed world. Its causes are not fully understood, but
are largely believed to develop from hypoxic conditions of the
placenta.The placenta releases inflammatory factors, causing hypertension and proteinuria for the mother, as well as other side
effects. Fetal effects include growth restriction and the negative
effects related to premature birth. Risk factors are well-known
yet poorly understood, and prophylactic treatments such as
aspirin are available. Treatment for preeclampsia and eclampsia
now mainly revolve around symptoms, but experiments are underway which will hopefully lead to a greater understanding and
more effective treatment for this syndrome.

References
Abildgaard U, Heimdal K. Pathogenesis of the syndrome of
hemolysis, elevated liver enzymes, and low platelet count
(HELLP): A review. European journal of obstetrics, gynecology, and reproductive biology. 2013;166(2):117-123. http://
www.ncbi.nlm.nih.gov/pubmed/23107053. doi: 10.1016/j.
ejogrb.2012.09.026.
Duckitt K, Harrington D. Risk factors for pre-eclampsia at
antenatal booking: systematic review of controlled studies.
BMJ: British Medical Journal. 2005;330(7491):565. doi:10.1136/
bmj.38380.674340.E0.

Schmatz, M., Madan, J., Marino, T., & Davis, J. (2010). Maternal
obesity: The interplay between inflammation, mother and
fetus. Journal of Perinatology, 30(7), 441-6. doi:http://dx.doi.
org/10.1038/jp.2009.182
Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant
women. N Engl J Med. 1993;329(17):1213-1218. http://
dx.doi.org/10.1056/NEJM199310213291701. doi: 10.1056/
NEJM199310213291701.
Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter
study. American Journal of Obstetrics and Gynecology.
1995;172(2, Part 1):642-648. http://www.sciencedirect.
com/science/article/pii/0002937895905863. doi: //doi.
org/10.1016/0002-9378(95)90586-3.
Sibley CP. Treating the dysfunctional placenta. Journal of
Endocrinology. 2017;234(2):81-97. doi:10.1530/joe-17-0185.
Skjærven, R., PhD, Wilcox, Allen J, M.D., PhD., & Lie, R. T.,
PhD. (2002). The interval between pregnancies and the risk
of preeclampsia. The New England Journal of Medicine,
346(1), 33-8. Retrieved from https://search.proquest.com/
docview/223942760?accountid=14375
Wahabi, H. A., Fayed, A. A., Alzeidan, R. A., & Mandil, A. A. (2014).
The independent effects of maternal obesity and gestational diabetes on the pregnancy outcomes. BMC Endocrine Disorders,
14, 47. doi:http://dx.doi.org/10.1186/1472-6823-14-47
Wang C, Liu X, Kong D, et al. Apelin as a novel drug for treating
preeclampsia. Experimental and Therapeutic Medicine. October
2017:5917-23. doi:10.3892/etm.2017.5304.

Duley L. The global impact of pre-eclampsia and eclampsia.
Seminars in Perinatology. 2009;33(3):130-137. http://www.
sciencedirect.com/science/article/pii/S0146000509000214. doi:
10.1053/j.semperi.2009.02.010.
Jeyabalan, A., Powers, R. W., Durica, A. R., Harger, G. F., Roberts,
J. M., & Ness, R. B. (2008). Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. American Journal
of Hypertension, 21(8), 943-7. doi:http://dx.doi.org/10.1038/
ajh.2008.219
Levine, Richard J, M.D., M.P.H., Maynard, S. E., M.D., Qian, C.,
M.S., Lim, K., M.D., England, Lucinda J, M.D., M.S.P.H.,Yu, K. F.,
PhD., Karumanchi, S. A. (2004). Circulating angiogenic factors
and the risk of preeclampsia. The New England Journal of
Medicine, 350(7), 672-83. Retrieved from https://search.
proquest.com/docview/223937561?accountid=14375
Papadakis MA, McPhee SJ. Preeclampsia & eclampsia. In: Quick
medical diagnosis & treatment 2017. New York, NY: McGrawHill Education; 2017. accessmedicine.mhmedical.com/content.
aspx?aid=1139407864. Accessed 2017/11/18.
Redman, C. W., & Sargent, I. L. (2005). Latest advances in understanding preeclampsia. Science, 308(5728),
1592-4. Retrieved from https://search.proquest.com/
docview/213613158?accountid=14375

19

